Keyphrases
Randomized Phase II Trial
100%
Zoledronic Acid
100%
Phase II Trial
100%
Locally Advanced Breast Cancer
100%
Disseminated Tumor Cells
100%
Bone Marrow
38%
Acid Groups
30%
Timing of Surgery
23%
Disease Progression
15%
Breast Cancer
15%
Docetaxel
15%
Epirubicin
15%
Randomized Trial
7%
Number of Patients
7%
Renal Function
7%
Newly Diagnosed
7%
Chemotherapy
7%
Bone Marrow Samples
7%
2-cycles
7%
Disease-free Survival
7%
Stage II-III
7%
Thrombosis
7%
Bone Loss
7%
Study Support
7%
Single Center
7%
Bisphosphonates
7%
Cardiac Function
7%
Neoadjuvant
7%
Liver Function
7%
Neoadjuvant Chemotherapy
7%
Pfizer
7%
Severe Diarrhea
7%
Through Effect
7%
Novartis
7%
4-cycle
7%
Patients with Breast Cancer
7%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
7%
Osteonecrosis
7%
Antimetastatic Effect
7%
Allocation Concealment
7%
Medicine and Dentistry
Metastatic Carcinoma
100%
Locally Advanced Breast Cancer
100%
Zoledronic Acid
100%
Breast Cancer
23%
Disease Exacerbation
15%
Docetaxel
15%
Epirubicin
15%
Infection
7%
Diarrhea
7%
Kidney Function
7%
Clinical Stage
7%
Bone Necrosis
7%
Oncology
7%
Thrombosis
7%
Osteolysis
7%
Neoadjuvant Chemotherapy
7%
Heart Function
7%
Disease Free Survival
7%
Bisphosphonate
7%
Liver Function
7%
Drug
7%
Chemotherapy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Zoledronic Acid
100%
Metastasis
100%
Chemotherapy
15%
Disease Exacerbation
15%
Epirubicin
15%
Docetaxel
15%
Infection
7%
Diarrhea
7%
Disease Free Survival
7%
Bisphosphonic Acid Derivative
7%
Thrombosis
7%
Drug
7%
Bone Necrosis
7%